search
Back to results

Intestinal Stem Cells Characterization (BIODIGE)

Primary Purpose

Inflammatory Bowel Diseases

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Endoscopic biopsies
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Inflammatory Bowel Diseases

Eligibility Criteria

3 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: patient must have a coloscopy for intestinal pain -

Exclusion Criteria: cancer

-

Sites / Locations

  • Hopital des EnfantsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Sham Comparator

Arm Label

Crohn disorder

FAP (familial adenomatous polyposis )

ulcerative colitis

witness

Arm Description

arm composed by 30 patients with Crohn disorder

arm composed by 30 patients with FAP disorder

arm composed by 30 patients with ulcerative colitis

arm composed by 30 patients with no intestinal disorders

Outcomes

Primary Outcome Measures

number of organoids
number of organoids in culture wells during the follow-up

Secondary Outcome Measures

mean size of organoids
mean diameter of organoids in culture wells during the follow-up
percentage of different types of organoids
organoids are differentiated by the size of the epithelial cell border and by the presence or absence of buds

Full Information

First Posted
May 13, 2016
Last Updated
August 22, 2023
Sponsor
University Hospital, Toulouse
search

1. Study Identification

Unique Protocol Identification Number
NCT02874365
Brief Title
Intestinal Stem Cells Characterization
Acronym
BIODIGE
Official Title
Intestinal Stem Cells Characterization in Intestinal Organoid Culture From Inflammatory Bowel Disease and Intestinal Polyposis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2016 (undefined)
Primary Completion Date
December 2022 (Actual)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A monocentric pilot studying intestinal organoids from endoscopic biopsies of IBD (Crohn and ulcerative colitis), FAP patients and healthy controls. Investigate the morphological characteristics of organoids, the expression of genes and proteins of the Wnt/APC/beta-catenin pathway within both ISC.
Detailed Description
Intestinal organoids are 3D mini-guts produced in vitro based on intestinal stem cell (ISC) capabilities. These organoids contain all of the intestinal epithelial cells. The renewal of the two kinds of ISCs, which are present at the bottom of intestinal crypts, is controlled by Wnt/APC/beta-catenin pathway. Mutations of genes involved in this pathway are found in intestinal polyposes like familial adenomatous polyposis (FAP, APC gene). This model is of interest to study early pathophysiological events occurring within intestinal epithelium, in the context of FAP and inflammatory bowel diseases (IBD). An excessive proliferation or an abnormal healing is found in FAP and IBD respectively. Investigators hypothesized that it could specifically involved one of the 2 ISCs. Columnar basal cells (CBC) and ISC located at the +4 position from the bottom of the crypt (ISC+4) can both differentiate into absorptive or secretory intestinal epithelial cells. However, CBC and ISC+4 could have different metabolic, migratory functions, or stress survival. Investigators designed a monocentric pilot study to develop intestinal organoids from endoscopic biopsies of IBD (Crohn and ulcerative colitis), FAP patients and healthy controls. Investigators plan to investigate the morphological characteristics of organoids, the expression of genes and proteins of the Wnt/APC/beta-catenin pathway within both ISC. Will also be studied the expression of key genes of tumor initiation (PTEN, BMPR1A, p53 and KRAS) and inflammatory parameters (cytokines and lipid mediators). The results of this study could improve the understanding of intestine renewal. Later on, the development of new drugs could beneficiate to IBD and FAP patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammatory Bowel Diseases

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Crohn disorder
Arm Type
Experimental
Arm Description
arm composed by 30 patients with Crohn disorder
Arm Title
FAP (familial adenomatous polyposis )
Arm Type
Experimental
Arm Description
arm composed by 30 patients with FAP disorder
Arm Title
ulcerative colitis
Arm Type
Experimental
Arm Description
arm composed by 30 patients with ulcerative colitis
Arm Title
witness
Arm Type
Sham Comparator
Arm Description
arm composed by 30 patients with no intestinal disorders
Intervention Type
Procedure
Intervention Name(s)
Endoscopic biopsies
Intervention Description
intestinal biopsies
Primary Outcome Measure Information:
Title
number of organoids
Description
number of organoids in culture wells during the follow-up
Time Frame
2 days
Secondary Outcome Measure Information:
Title
mean size of organoids
Description
mean diameter of organoids in culture wells during the follow-up
Time Frame
2 days
Title
percentage of different types of organoids
Description
organoids are differentiated by the size of the epithelial cell border and by the presence or absence of buds
Time Frame
2 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patient must have a coloscopy for intestinal pain - Exclusion Criteria: cancer -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Emmanuel MAS, MD, PhD
Phone
33 5 61 77 86 03
Email
mas.e@chu-toulouse.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emmanuel MAS, MD, PhD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital des Enfants
City
Toulouse
ZIP/Postal Code
31159
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmanuel MAS, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26645664
Citation
Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015 Dec;25:56-61. doi: 10.1016/j.coph.2015.11.003. Epub 2015 Nov 29.
Results Reference
background

Learn more about this trial

Intestinal Stem Cells Characterization

We'll reach out to this number within 24 hrs